Transcript TisXell - Cell D

Dr Mark Chong
National University of Singapore
Dept of Obstetrics and
Gynaecology
 2nd
most transplanted tissue
• 1 million cases annually in US alone
 Current
treatment:
• Autograft: Site morbidity
• Allograft: Donor shortage, immune rejection
 Solution: Tissue
Engineering
 Resorbable
scaffolds + osteogenic cells
 Mature in bioreactor  TisXell System
 Note:
• Function of bone is primarily structural
•  low hanging fruit
Mesencymal
stem cells
(MSC)
TisXell
Day 0
Day 14
Increased
cellular
proliferation
Day 28
Increased
mineralisation
TisXell
Day 0
Day 14
Increased
Increased
viability
cellular
proliferation
Live
Dead
Day 28
Increased
mineralisation
TisXell


Created 7 mm defect
Press-fit 8 mm graft
S
S
S
S
S
S

TisXell stimulates bone formation
• 5.7 x more mineralisation than static

TisXell generated bone grafts are highly
efficacious
• Rapid healing of fracture within 3 months vs non-
union
 Minipig
model
 Larger volume, anticipate issues of
vascularisation
 Introduce endothelial progenitor cells
(EPC) into cellular mix
Mesencymal
stem cells
(MSC)
Endothelial
Progenitor
Cells (EPC)
MSC
EPC
 TisXell
supports
co-culture
of different
cell types
 18
mm segmental defect in tibia
 Monitor over 12 months:
• X-ray, CT, angiography
fMSC-EPC
MSC
1 mth
3 mth
1 mth
MSC
1 mth
3 mth
fMSC-EPC
1 mth
6 pigs implanted with TisXell cultured
TEBG
 All pigs survived; no adverse reaction
 Mineralisation and bridging evident at 3
mths in MSC group; 1 mth in fMSC-EPC
group
 Studies to continue for long-term safety
data (12 months)

TisXell provides a controlled and
conducive environment for generating
TEBG implant
 Potent osteo-stimulatory cues
 Efficacy demonstrated in rat model
 Potentially faster bone regeneration and
vascularisation in minipig model
 Preparatory work with clinicians for
Clinical Phase I trial
